GLP1R and polycystic ovary syndrome: As opposed to long acting GLP-1 agonist liraglutide, the only report using short acting GLP-1 agonist exenatide in treatment-naive overweight patients with PCOS was a 24 week-study conducted to evaluate change in menstrual frequency whereas change in body weight was pre-specified as secondary outcome.